Eton Pharmaceuticals, Inc. (ETON) Q3 2026 earnings results
Eton Pharmaceuticals, Inc. (ETON) reported Q3 2026 results on Nov 5, 2026, 4:13:25 PM ET: adjusted EPS $0.50 vs. $0.37 expected (beat by 35.1%); revenue $57.92M vs. $42.21M expected (beat by 37.2%). Outlook: The Company expects 2026 revenue of more than $175 million and at least a 40% Adjusted EBITDA margin.
| Metric | Reported | Analyst estimate | Result |
|---|---|---|---|
| EPS (adjusted, diluted) | $0.50 | $0.37 | Beat by 35.1% |
| Revenue | $57.92M | $42.21M | Beat by 37.2% |
Analyst estimate: the average forecast before the release.
Source
Figures from the SEC 8-K filing, released Nov 5, 2026, 4:13:25 PM ET. Nexqual published them 40 seconds after release. Each figure is confirmed by two independent extraction methods before it is published.
Year over year
Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 157.9% from $22.46M.
Stock reaction
The results came out after the market closed. ETON closed at $56.46 on November 6, 2026, up 19.7% from its $47.15 close on November 5, 2026 before the results. Latest: $66.63 as of 11:40 AM ET, +41.3% since the pre-release close.
Questions and answers
Did Eton Pharmaceuticals, Inc. beat earnings expectations?
Yes. Eton Pharmaceuticals, Inc. reported adjusted EPS of $0.50 against an average analyst estimate of $0.37 (beat by 35.1%), and revenue of $57.92M against $42.21M expected (beat by 37.2%).
What were Eton Pharmaceuticals, Inc.'s Q3 2026 earnings and revenue?
adjusted diluted EPS of $0.50 and revenue of $57.92M. Compared with the same quarter a year earlier (ended September 30, 2025, from the company's SEC filing): revenue grew 157.9% from $22.46M.
When did Eton Pharmaceuticals, Inc. report Q3 2026 earnings?
Nov 5, 2026, 4:13:25 PM ET, in an SEC 8-K filing (Item 2.02).
How did ETON stock react to the earnings?
The results came out after the market closed. ETON closed at $56.46 on November 6, 2026, up 19.7% from its $47.15 close on November 5, 2026 before the results. Latest: $66.63 as of 11:40 AM ET, +41.3% since the pre-release close.
What did Eton Pharmaceuticals, Inc. say about its outlook?
The Company expects 2026 revenue of more than $175 million and at least a 40% Adjusted EBITDA margin.
More on ETON
ETON stock page: price, SEC financials, insider trades, superinvestor holders, analyst estimates and options. All results reported that day: earnings November 5, 2026.
Source: SEC EDGAR 8-K (Item 2.02), Nexqual Earnings Flash. Built November 10, 2026 at 16:40 UTC. Not investment advice.
Data source: Nexqual. Last updated: November 10, 2026 at 16:40 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt